Abstract:Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (CT) is the standard care for stage II–IV nasopharyngeal carcinoma (NPC) in NCCN guideline. CCRT has been shown to improve outcomes for stage III–IV NPC patients over radiation therapy (RT) alone, but the benefit for stage II NPC patients is controversial, especially in the era of intensity-modulated radiation therapy (IMRT). The study is to evaluate and determine the role of CCRT in stage II NPC underwent IMRT. Patients with stage II NPC (T1N1, T2N0, or T2N1; 7th ed AJCC staging) were recruited from January 2009 to June 2015 at 6 centers in China. They were randomly assigned to CCRT followed by adjuvant CT (CCRT+CT) arm or RT alone arm. All patients were treated with IMRT. The chemotherapy consisted of concurrent cisplatin (80 mg/m2 on day 1, 22, 43) during IMRT and 3 cycles of adjuvant CT with cisplatin 75mg/m2 day 1, 5-FU 750 mg/m2 24h-continuous infusion day 1-5 every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included locoregional failure-free survival (LRFFS), distant metastasis-free survival (DMFS), and toxicities. Survivals were calculated with Kaplan-Meier method. The differences between survivals were calculated by Log-rank test. Toxic effects were analyzed using the χ2 test. All statistical tests were two-side. A total of 168 patients were recruited and 160 were eligible for intent-for-treat analysis. 81 patients were assigned to CCRT+CT arm and 79 in RT alone arm. With a median follow-up of 61.5 months, the 3 -year and 5-year OS of all patients were 93.75% and 90.00%, respectively. The 3-year and 5-year OS of CCRT+CT arm were 93.83%, 91.36%, respectively, and 93.67% and 88.61% in RT arm, respectively. There was no significant difference in OS between two arms (P = 0.562). The 3-year and 5-year LRFFS of CCRT+CT arm were 97.53%, 96.26%, respectively, and 94.94% and 93.67% in RT arm, respectively. There was no significant difference in LRFFS between two arms (P = 0.690). The 3-year and 5-year DMFS of CCRT+CT arm were 93.82%, 93.82%, respectively, and 96.20% and 93.67% in RT arm, respectively. There was also no significant difference in DMFS between two arms (P = 0.967). There were higher local radiation acute and late side effects in the CCRT+CT arm than RT arm although not reached significant. There were significantly higher acute systemic side effects in the CCRT+CT arm, especially the incidence of grade 3-4 hematologic and gastrointestinal reactions (P =0.000). Most of locoregional recurrence (6/8, 75.00%) and distant metastases (6/7, 85.71%) occurred in the T2N1M0 group. For stage II NPC patients treated with IMRT, CCRT and adjuvant CT did not improve OS, LRFFS and DMFS. But there were more significant toxicities. Chemotherapy may not be necessary in these patients. However, further research with longer follow up is needed especially for those with T2N1 disease.

Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients

A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy versus Radiotherapy Alone in the Treatment of Stage II and T3N0M0 Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.

An Analysis of Efficacy of Intensity-Modulated Radiotherapy with Concurrent Chemotherapy for Stage T1-2 N1 Nasopharyngeal Carcinoma

Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study

Chemotherapy May Not Be Necessary in Stage II Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy

Intensity-modulated Radiation Therapy Versus 2D-RT or 3D-CRT for the Treatment of Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Comparison of long-term efficacy between concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

The Role of Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era: A Systematic Review and Meta-Analysis

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma

Oncologic Outcomes of IMRT Versus CRT for Nasopharyngeal Carcinoma

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.

Efficacy of Concurrent Chemoradiotherapy in Subgroups of Stage III Nasopharyngeal Carcinoma: an Analysis Based on 10-Year Follow-Up

Comparison of long-term efficacy between concurrent chemoradiotherapy and intensity-modulated radiotherapy alone for stage Ⅱ nasopharyngeal carcinoma

How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?

Role of Sequential Chemoradiotherapy in Stage II and Low-Risk Stage III–IV Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy: A Propensity Score-Matched Analysis

The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.

Chemo-radiotherapy Versus Radiotherapy Alone for Nasopharyngeal Carcinoma: A Meta-Analysis of 78 Randomized Controlled Trials (rcts) from English and Non-English Databases

The Role of Concurrent Chemoradiotherapy plus Adjuvant Chemotherapy to Radiotherapy Alone in the Treatment of Locally Advanced Nasopharyngeal Carcinoma:A Meta-analysis

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy: a Meta-Analysis